3.67
price up icon6.69%   0.23
after-market 시간 외 거래: 3.72 0.05 +1.36%
loading
전일 마감가:
$3.44
열려 있는:
$3.47
하루 거래량:
5.17M
Relative Volume:
0.93
시가총액:
$323.90M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.2378
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
+1.10%
1개월 성능:
-10.05%
6개월 성능:
-42.83%
1년 성능:
-45.22%
1일 변동 폭
Value
$3.4286
$3.70
1주일 범위
Value
$3.35
$3.70
52주 변동 폭
Value
$2.90
$11.16

알티뮨 Stock (ALT) Company Profile

Name
명칭
Altimmune Inc
Name
전화
(240) 654-1450
Name
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
직원
59
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
ALT's Discussions on Twitter

ALT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ALT
Altimmune Inc
3.67 303.60M 409.00K -101.35M -71.49M -1.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
389.08 99.27B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
586.96 62.28B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.18 59.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
707.96 43.34B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
300.14 36.72B 3.81B -644.79M -669.77M -6.24

알티뮨 Stock (ALT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-10 재개 Goldman Sell
2025-02-28 개시 William Blair Mkt Perform
2025-01-08 개시 Stifel Buy
2024-11-12 개시 UBS Buy
2024-04-29 다운그레이드 Guggenheim Buy → Neutral
2024-01-24 개시 Goldman Neutral
2023-03-22 다운그레이드 Goldman Buy → Neutral
2022-12-01 개시 Goldman Buy
2021-12-29 재개 Jefferies Buy
2021-06-02 개시 H.C. Wainwright Buy
2021-02-11 개시 Guggenheim Buy
2020-12-14 개시 Jefferies Buy
2020-11-12 재확인 B. Riley Securities Buy
2020-09-25 개시 B. Riley FBR Buy
2020-08-14 개시 Evercore ISI Outperform
2020-07-31 개시 Piper Sandler Overweight
2020-07-28 개시 JMP Securities Mkt Outperform
2020-02-24 재개 ROTH Capital Buy
2019-07-19 개시 ROTH Capital Buy
2017-10-09 개시 Piper Jaffray Overweight
모두보기

알티뮨 주식(ALT)의 최신 뉴스

pulisher
05:17 AM

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade) (NASDAQ:ALT) - Seeking Alpha

05:17 AM
pulisher
04:37 AM

Altimmune (ALT) Stock Rises on FDA's Acceptance of Surrogate Endpoint - GuruFocus

04:37 AM
pulisher
04:18 AM

Will Altimmune Inc. price bounce be sustainableBond Market & Consistent Profit Trade Alerts - Newser

04:18 AM
pulisher
04:03 AM

ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

04:03 AM
pulisher
04:00 AM

ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.

04:00 AM
pulisher
09:40 AM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - PR Newswire

09:40 AM
pulisher
Aug 26, 2025

Using Python tools to backtest Altimmune Inc. strategiesPortfolio Risk Summary & Growth Focused Entry Point Reports - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Altimmune Inc. stock volume spike explainedTrend Reversal & Accurate Entry/Exit Alerts - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Top chart patterns to watch in Altimmune Inc.2025 Momentum Check & Weekly Breakout Watchlists - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Contact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT) - PR Newswire

Aug 26, 2025
pulisher
Aug 26, 2025

Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire

Aug 26, 2025
pulisher
Aug 26, 2025

Altimmune to Participate in Upcoming Investor Conferences - The Manila Times

Aug 26, 2025
pulisher
Aug 26, 2025

Late-Stage Biotech Altimmune Announces Triple Conference Presence: Wells Fargo, HC Wainwright, Morgan Stanley - Stock Titan

Aug 26, 2025
pulisher
Aug 25, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT - WV News

Aug 25, 2025
pulisher
Aug 25, 2025

Levi & Korsinsky Moves to SueWallSt for Altimmune, Inc. Investors That Lost Money - Stockhouse

Aug 25, 2025
pulisher
Aug 24, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire

Aug 24, 2025
pulisher
Aug 24, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Aug 24, 2025
pulisher
Aug 24, 2025

Is Altimmune Inc. still worth holding after the dip2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser

Aug 24, 2025
pulisher
Aug 24, 2025

Real time breakdown of Altimmune Inc. stock performanceJuly 2025 Recap & Free Technical Pattern Based Buy Signals - Newser

Aug 24, 2025
pulisher
Aug 22, 2025

Class Action Filed Against Altimmune, Inc. (ALT)October 6, 2025 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire

Aug 22, 2025
pulisher
Aug 21, 2025

Altimmune, Inc. Sued for Securities Law Violations - GlobeNewswire

Aug 21, 2025
pulisher
Aug 21, 2025

Faruqi & Faruqi investigates potential claims against Altimmune, Inc. - AInvest

Aug 21, 2025
pulisher
Aug 20, 2025

ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc. - PR Newswire

Aug 20, 2025
pulisher
Aug 20, 2025

Will Altimmune Inc. continue its uptrend2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Aug 20, 2025
pulisher
Aug 19, 2025

Altimmune wins FDA fast track status for alcohol use disorder therapy - MSN

Aug 19, 2025
pulisher
Aug 19, 2025

Will Altimmune Inc. stock recover after recent dropQuarterly Market Summary & Precise Trade Entry Recommendations - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Altimmune Inc (ALT) Stock: A Comprehensive 52-Week Review - investchronicle.com

Aug 19, 2025
pulisher
Aug 19, 2025

ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 19, 2025
pulisher
Aug 19, 2025

Altimmune (ALT) Gains FDA Fast Track for Alcohol Use Disorder Treatment - GuruFocus

Aug 19, 2025
pulisher
Aug 19, 2025

Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - MarketScreener

Aug 19, 2025
pulisher
Aug 19, 2025

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times

Aug 19, 2025
pulisher
Aug 19, 2025

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) | ALT Stock News - GuruFocus

Aug 19, 2025
pulisher
Aug 19, 2025

Altimmune's Pemvidutide Receives FDA Fast Track Designation for Alcohol Use Disorder Treatment - Quiver Quantitative

Aug 19, 2025
pulisher
Aug 19, 2025

Trend analysis for Altimmune Inc. this weekMarket Activity Recap & Scalable Portfolio Growth Ideas - Newser

Aug 19, 2025
pulisher
Aug 18, 2025

Lost Money on Altimmune, Inc. (ALT)? Join Class Action Before October 6, 2025Contact Levi & Korsinsky - ACCESS Newswire

Aug 18, 2025
pulisher
Aug 18, 2025

Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel - GlobeNewswire

Aug 18, 2025
pulisher
Aug 18, 2025

Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights - PR Newswire

Aug 18, 2025
pulisher
Aug 18, 2025

ALT LAWSUIT ALERT: The Gross Law Firm Notifies Altimmune, - GlobeNewswire

Aug 18, 2025
pulisher
Aug 18, 2025

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. LawsuitALT - PR Newswire

Aug 18, 2025
pulisher
Aug 18, 2025

Altimmune Inc. stock trend outlook and recovery pathWeekly Trend Report & Low Drawdown Investment Strategies - Newser

Aug 18, 2025

알티뮨 (ALT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$24.78
price up icon 0.98%
$84.84
price up icon 1.00%
$24.80
price down icon 8.06%
$103.01
price down icon 1.70%
$134.53
price up icon 1.79%
biotechnology ONC
$300.14
price down icon 2.84%
자본화:     |  볼륨(24시간):